Valuation Discrepancy: NVO vs. LLY A side-by-side comparison reveals that investors are heavily penalizing Novo Nordisk for its pipeline setbacks while pricing Eli Lilly for near perfection.
Full analysis
Company #1 — The GPU Whisperer
Secret weapon connecting massive GPUs inside AI data centers. NVIDIA partner, 35% sales growth.
Company #2 — Pure Photonics Network
Moves data as light between cities — slashes networking power by 70%.
Company #3 — Silicon-to-Light Makers
Turns electrical signals into light inside AI centers; multi-billion NVIDIA partnership.
| Financial Metric | Novo Nordisk (NVO) | Eli Lilly (LLY) | | :— | :— | :— | | Market Capitalization | ~$142B – $199B | ~$1.01T – $1.02T | | Price-to-Earnings (P/E) TTM | ~10.58x – 11.6x | ~37.73x – 39.7x | | Price-to-Sales (P/S) | ~3.74x – 4.0x | ~12.56x | | Dividend Yield | ~4.13% – 4.17% | ~0.60% | | Gross Margin | 78.2% – 86.0% | 81.9% |
Price-to-Earnings (P/E) Ratio: Novo Nordisk is currently trading at a highly compressed Trailing Twelve Month (TTM) P/E ratio in the 10.58x to 11.6x range [cite: 5, 53]. In stark contrast, Eli Lilly trades at a premium multiple of roughly 37.73x [cite: 5, 6]. Historical Discount: A P/E ratio of ~11x is essentially 55% below Novo Nordisk's own 10-year historical median of 23.69x [cite: 54]. Price-to-Sales (P/S): NVO trades at a P/S ratio of roughly 3.74x to 4.0x, significantly lower than its five-year average of 8.6x, and vastly cheaper than LLY’s 12.56x [cite: 5, 53]. Intrinsic Value: Quantitative models calculate Novo Nordisk's intrinsic value at substantially higher than current trading metrics. With the stock trading in the low $40s, algorithmic models flag the equity as severely undervalued, representing a deep margin of safety for long-term holders [cite: 9, 54, 55].
Which Coin Could Make You Rich? (Play Your Pick)
This valuation gap suggests that the market believes Eli Lilly's dual-agonist and triple-agonist pipeline will eventually dominate the obesity market, rendering older single-agonist GLP-1s obsolete. However, considering Novo Nordisk generates superior gross margins and commands massive global volume share (treating nearly 5 million people globally with obesity medications), the compressed multiple suggests that potential negative outcomes are already thoroughly priced into the stock [cite: 32, 41].
Risks, Red Flags, and Open Questions
While the valuation is undemanding and the dividend is secure, an objective equity analysis must explicitly outline the systemic risks threatening Novo Nordisk's forward-looking guidance. Management has already lowered full-year 2026 adjusted operating profit growth expectations to a flat-to-negative range of 0% to -6% (at Constant Exchange Rates) compared to 2025, heavily impacted by US pricing adjustments [cite: 8, 32, 40].
Capacity Constraints and Supply Rationing
The most immediate operational risk is manufacturing capacity. Demand for GLP-1 pens vastly exceeds global supply. Novo Nordisk is attempting to solve this via brute force capital expenditure, projecting DKK 55 billion in CAPEX for 2026 alone and deploying DKK 129 billion in prior cycles to acquire Catalent facilities and expand internal sites [cite: 8, 34].
However, integrating these facilities, overcoming macromolecule active pharmaceutical ingredient (API) synthesis bottlenecks, and mastering sterile fill-finish processing takes years. How is Novo Nordisk managing the supply gap right now? To mitigate immediate shortages and protect the continuity of care for existing patients stabilized on higher maintenance doses, Novo Nordisk has had to strategically restrict shipments of lower starter doses (e.g., 0.25 mg, 0.5 mg, and 1.0 mg) of Wegovy in certain markets. While necessary from a patient-safety and ethical standpoint, this rationing policy artificially caps new patient starts, suppressing revenue momentum and providing an open door for competitors to snatch unserved market share [cite: 56, 57].
Pricing Pressures and Market Access
Novo Nordisk's profitability is highly sensitive to the US healthcare market, which is increasingly hostile to the list prices of obesity medications. The aforementioned 340B Drug Pricing Program adjustments highlight the immense power of institutional payers and government mandates to claw back revenue [cite: 8, 31, 37]. As cheaper copycats, compounded versions, and next-generation competitors hit the market, net realized prices per patient will inevitably decline. The company must offset this margin compression through pure volume growth, which loops back directly into the capacity constraint risk [cite: 41].
The Durability Dilemma
Finally, the clinical victory in the STEP Young pediatric trial masks a deeper, existential question for the entire GLP-1 asset class: durability. If a 6-year-old child successfully loses 40% of their excess BMI on semaglutide, what happens at age 10, 15, or 20? Adult trials clearly demonstrate that cessation of GLP-1 therapy results in rapid, near-total weight regain [cite: 11, 14, 16]. There is virtually zero longitudinal data on the biological or psychological impact of starting and stopping these powerful hormones in prepubescent patients over decades. If future longitudinal studies reveal adverse metabolic rebounds, or if payers refuse to fund lifelong pediatric prescriptions, the total addressable market could collapse from chronic lifelong management back down to short-term, acute interventions.
Sources: 1. novonordisk.com 2. nasdaq.com 3. biopharminternational.com 4. biospace.com 5. portfolioslab.com 6. financecharts.com 7. koalagains.com 8. finsee.ai 9. gurufocus.com 10. biggo.com 11. contemporarypediatrics.com 12. nordiclifescience.org 13. fiercepharma.com 14. 247wallst.com 15. webull.com 16. withpower.com 17. drsobo.com 18. drugtopics.com 19. belite.com 20. pharmacally.com 21. hcplive.com 22. morningstar.com 23. firstwordpharma.com 24. biospace.com 25. oup.com 26. allsci.com 27. tctmd.com 28. biospace.com 29. clinicaltrialsarena.com 30. managedhealthcareexecutive.com 31. globenewswire.com 32. quartr.com 33. spglobal.com 34. novonordisk.com 35. klrd.gov 36. doctronic.ai 37. novonordisk-us.com 38. sec.gov 39. reddit.com 40. globenewswire.com 41. investing.com 42. novonordisk.com 43. fullratio.com 44. stockevents.app 45. eulerpool.com 46. simplywall.st 47. tipranks.com 48. biospace.com 49. biospace.com 50. alphaspread.com 51. gurufocus.com 52. stockanalysis.com 53. fool.com 54. gurufocus.com 55. seekingalpha.com 56. wegovy.com 57. walgreens.com
For informational purposes only; not investment advice.